D A Park1, D H Lee2, S W Kim3, S H Lee4. 1. Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea. 2. Clinical Research Center, Woosuk University Korean Medicine Hospital, Jeonju, South Korea. 3. Department of Gynaecology, Yonsei University College of Medicine, Seoul, South Korea. 4. Department of Nursing Science, College of Nursing, Gachon University, Incheon, South Korea. Electronic address: sunarea87@gachon.ac.kr.
Abstract
AIM: This study aimed to evaluate the surgical safety and clinical effectiveness of RH compared to OH and LH for endometrial cancer. METHODS: We searched Ovid-Medline, Ovid-EMBASE, and the Cochrane library for studies published through May 2015. The outcomes of interest included safety (overall; peri-operative and post-operative complications; death within 30-days; and specific morbidities), effectiveness (survival, recurrence, length of stay [LOS], estimated blood loss [EBL], and operative time [OT]), and patient-reported outcomes (pain score, pain medication use, length of pain medication use, and time to return to work). Two independent reviewers extracted data and assessed the risk of bias. RESULTS: Twenty-four studies comparing RH to OH and 24 comparing RH to LH were identified. No significant differences were found in survival outcomes. The LOS was shorter, there was less EBL, and the rates of complications, readmission, and transfusion were lower with RH compared to OH. However, RH showed a longer OT and a higher incidence of vaginal cuff dehiscence compared to those for OH. Compared to LH, the LOS was shorter, there was less EBL, and the rates of conversion to laparotomy, intra-operative complications, urinary tract injuries, and cystotomy were lower in RH. Several patient-reported outcomes showed a significant benefit of RH, but each outcome was reported in only one study. CONCLUSIONS: RH may be a generally safer and better option than OH and LH for patients with endometrial cancer. Further prospective studies with long-term follow-up are required.
AIM: This study aimed to evaluate the surgical safety and clinical effectiveness of RH compared to OH and LH for endometrial cancer. METHODS: We searched Ovid-Medline, Ovid-EMBASE, and the Cochrane library for studies published through May 2015. The outcomes of interest included safety (overall; peri-operative and post-operative complications; death within 30-days; and specific morbidities), effectiveness (survival, recurrence, length of stay [LOS], estimated blood loss [EBL], and operative time [OT]), and patient-reported outcomes (pain score, pain medication use, length of pain medication use, and time to return to work). Two independent reviewers extracted data and assessed the risk of bias. RESULTS: Twenty-four studies comparing RH to OH and 24 comparing RH to LH were identified. No significant differences were found in survival outcomes. The LOS was shorter, there was less EBL, and the rates of complications, readmission, and transfusion were lower with RH compared to OH. However, RH showed a longer OT and a higher incidence of vaginal cuff dehiscence compared to those for OH. Compared to LH, the LOS was shorter, there was less EBL, and the rates of conversion to laparotomy, intra-operative complications, urinary tract injuries, and cystotomy were lower in RH. Several patient-reported outcomes showed a significant benefit of RH, but each outcome was reported in only one study. CONCLUSIONS:RH may be a generally safer and better option than OH and LH for patients with endometrial cancer. Further prospective studies with long-term follow-up are required.
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Slavcho T Tomov; Grigor A Gorchev; Desislava K Kiprova; Aleksandar D Lyubenov; Nadezhda H Hinkova; Vesela D Tomova; Zornitsa V Gorcheva; Sarfraz Ahmad Journal: J Robot Surg Date: 2022-02-10
Authors: Thomas Papathemelis; Helen Oppermann; Stella Grafl; Michael Gerken; Armin Pauer; Sophia Scharl; Anton Scharl; Elisabeth Inwald; Atanas Ignatov; Olaf Ortmann; Monika Klinkhammer-Schalke; Alexander Hein; Matthias W Beckmann; Michael P Lux Journal: J Cancer Res Clin Oncol Date: 2020-01-04 Impact factor: 4.553
Authors: Benjamin D Beran; Marie Shockley; Pamela Frazzini Padilla; Sara Farag; Pedro Escobar; Stephen Zimberg; Michael L Sprague Journal: JSLS Date: 2018 Apr-Jun Impact factor: 2.172